Peter M Voorhees

List of Publications by Year
in descending order

14 papers	1,863 citations	1162889 8 h-index	1125617 13 g-index
14 all docs	14 docs citations	14 times ranked	2671 citing authors

#	Article	IF	Citations
1	Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. Cancer Medicine, 2021, 10, 6933-6936.	1.3	9
2	A phase I/<scp>II</scp> study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance <scp>A061202</scp>). American Journal of Hematology, 2021, 96, 1595-1603.	2.0	15
3	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood, 2016, 128, 37-44.	0.6	347
4	Corrigendum to â€œMeasurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assaysâ€•[Thromb. Res. 139 (2016) 90â€“97]. Thrombosis Research, 2016, 147, 63.	0.8	0
5	Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays. Thrombosis Research, 2016, 139, 90-97.	0.8	70
6	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet, The, 2016, 387, 1551-1560.	6.3	724
7	Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius). Blood, 2015, 126, 1829-1829.	0.6	11
8	Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab. Blood, 2015, 126, 3571-3571.	0.6	8
9	Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective. Blood, 2015, 126, 4254-4254.	0.6	2
10	Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma. Clinical Cancer Research, 2007, 13, 6469-6478.	3.2	112
11	Emerging Data on the Use of Anthracyclines in Combination with Bortezomib in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2007, 7, S156-S162.	1.4	8
12	Emerging Role of Novel Combinations for Induction Therapy in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 33-41.	1.4	7
13	THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY. Annual Review of Pharmacology and Toxicology, 2006, 46, 189-213.	4.2	251
14	The proteasome as a target for cancer therapy. Clinical Cancer Research, 2003, 9, 6316-25.	3.2	299